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ABSTRACT A solution structure for the complete zymogen form of human coagulation protein C is modeled. The initial core
structure is based on the x-ray crystallographic structure of the -carboxyglutamic acid (Gla)-domainless activated form. The
Gla domain (residues 1–48) is modeled from the x-ray crystal coordinates of the factor VIIa/tissue factor complex and oriented
with the epidermal growth factor-1 domain to yield an initial orientation consistent with the x-ray crystal structure of porcine
factor IXa. The missing C-terminal residues in the light chain (residues 147–157) and the activation peptide residues 158–169
were introduced using homology modeling so that the activation peptide residues directly interact with the residues in the
calcium binding loop. Molecular dynamics simulations (Amber-particle-mesh-Ewald) are used to obtain the complete
calcium-complexed solution structure. The individual domain structures of protein C in solution are largely unaffected by
solvation, whereas the Gla-epidermal growth factor-1 orientation evolves to a form different from both factors VIIa and IXa. The
solution structure of the zymogen protein C is compared with the crystal structures of the existing zymogen serine proteases:
chymotrypsinogen, proproteinase, and prethrombin-2. Calculated electrostatic potential surfaces support the involvement of
the serine protease calcium ion binding loop in providing a suitable electrostatic environment around the scissile bond for
IIa/thrombomodulin interaction.
INTRODUCTION
Protein C (PC), a vitamin K-dependent (VKD) plasma
serine protease zymogen (Mammen et al., 1960; Stenflo,
1976), is synthesized mainly in the liver and in endothelial
cells (Tanabe et al., 1991) as a single chain polypeptide. The
majority of the protein is converted into a two-chain disul-
fide-linked zymogen during secretion from the cell (Foster
et al., 1990; Grinnell et al., 1991). The structure of PC is
highly homologous to other VKD blood coagulation factors
VII, IX, and X. However, once activated by thrombin bound
to thrombomodulin on the endothelial cell surface, it func-
tions as a natural anticoagulant (for reviews on PC and its
activation, see Esmon and Esmon, 1984; Esmon, 1989,
1995a,b; Tuddenham and Cooper, 1994; Suzuki, 1995;
Davie, 1995). Genetic defects in the PC pathway are asso-
ciated with an increased risk for venous thrombosis (Re-
itsma, 1997). Deficiency of PC is one of the most common
causes of an inherited autosomal dominant thrombophilia.
The zymogen (see Fig. 1) contains a pre-pro leader pep-
tide (absent in the mature protein), a -carboxyglutamic
acid (Gla) domain of 9 Gla residues, a short helical hydro-
phobic amino acid stack, two epidermal growth factor
(EGF)-like domains, a linking peptide between the light
chain and the heavy chain, an activation peptide, and a
trypsin-like SP domain in which the catalytic triad is located
at His-211(cn57), Asp-257(cn102), and Ser-360(cn195)
(Fernlund and Stenflo, 1982; Stenflo and Fernlund, 1982;
Foster and Davie, 1984; Foster et al., 1985, 1987). Post-
translational modification removes the dipeptide Lys-156-
Arg-157, so that the single chain form is converted into a
two-chain molecule linked by a disulfide bond; 80% of the
zymogen PC circulating in plasma is in this form (Foster et
al., 1990; Grinnell et al., 1991). The activation, fluorescence
properties and amidolytic activity of the single- and two-
chain protein are identical (Rezaie and Esmon, 1995). Also,
carboxylation of Glu residues in the amino terminal Gla
domain (Stenflo, 1976; Kisiel et al., 1976), hydroxylation of
an Asp residue in the EGF1 domain (Drakenberg et al.,
1983; Fernlund and Stenflo, 1983) and glycosylation
(McClure et al., 1992; Grinnell et al., 1991) are post-
translational events.
Activation occurs when a negatively charged peptide
(Lys-158-Arg-169) is released by the cleavage of the pep-
tide bond between Arg-169 and Leu-170. Activated protein
C (APC), in the presence of cofactor protein S (PS), pro-
teolytically inactivates both factors Va and VIIIa on platelets
and endothelial cells (Fay et al., 1991; Kalafatis et al.,
1994). Recently, it has been shown that in addition to the
function of factor V as a procoagulant after its activation by
thrombin, factor V plays an important role in the anticoag-
ulant system as a phospholipid (PL)-bound cofactor to APC
(Dahlback and Hildebrand, 1994). It is also reported that
factor V acts synergistically with PS as PL-bound cofactors
in the presence of calcium ions (Dahlback and Hildebrand,
1994; Shen and Dahlback, 1994; Shen et al., 1997a; Dahl-
back, 1997). In a study using fluorescence resonance energy
transfer, Yegneswaran et al. (1997) concluded that the func-
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tion of PS as a cofactor for APC is to alter the active site
location of APC above the membrane surface. Yegneswaran
et al. (1997) also showed that the chimera protein obtained
by replacing the Gla domain of APC by that of prothrombin
alters the active site location above the membrane surface.
This chimera protein alone shows the same inactivation
rate of factor Va as the APCwild-type/PS complex. Factor Xa
also protects factor Va from inactivation by APC (Nesheim
et al., 1982; Jane et al., 1991). Both active and precursor
forms of factor X bind to factor Va with equal efficacy and
both compete with APC for its factor Va binding site (Jane
et al., 1991). In addition to its anticoagulant activity, APC
has also been shown to have profibrinolytic (Zolton and
Seegers, 1973; Comp and Esmon, 1981; De Fouw et al.,
1988), anti-ischemic, and anti-inflammatory (Esmon et al.,
1991) activities.
The solution of the x-ray crystal structure of a significant
portion of APC (Mather et al., 1996) provides an opportu-
nity to complete the zymogen structure by theoretical tech-
niques. Major advances of past decade in the quality of
force fields (Cornell et al., 1995; Cheatham et al., 1995),
molecular dynamics methodology (Essmann et al., 1995),
and parallel computers make such a substantial undertaking
possible. The hypothesis is that molecular dynamics (MD)
simulations, if firmly based on structure, are now reason-
ably accurate for time scales of nanoseconds.
We have developed herein a solvent-equilibrated model
for the complete zymogen PC in the presence of bound
calcium ions. The initial structure is based on the 2.8 Å
resolution x-ray crystal structure available for the Gla-
domainless human APC (Mather et al., 1996). Homology
modeling, described below in computational procedure, is
used to introduce the Gla domain, the following aromatic
amino acid stack, and the activation peptide. Molecular
dynamics (MD) simulations are used to obtain an accurate
solution structure of calcium-bound human PC. In the
present model, the carbohydrate chains are not included at
the four Asn-linked glycosylation sites that are post-trans-
lationally glycosylated in the circulating zymogen. Also, the
post-translationally removed Lys-156-Arg-157 dipeptide in
PC is present in the model, although this segment does not
appear to play a role in activation (Rezaie and Esmon,
1995). Comparison of the modeled zymogen structure with
the x-ray crystal structure of APC may clarify functional
activities of the enzyme form. Consequently, the structural
changes between the zymogen (solution model) and the
enzyme (x-ray) are compared with three other zymogen/
active SP systems for which x-ray crystal data are available
for both zymogen and active forms. Possible functional
roles of Gla and EGF1 domains and the high affinity cal-
cium ions bound to EGF1 and SP domains are also dis-
cussed. Whereas earlier modeling work focused on the
activated thrombin (IIa)-thrombomodulin (TM)-PC com-
plex in the absence of solvent or calcium ions (Knobe et al.,
1999) and on a static model that included the activation
peptide and SP domain only (Fisher et al., 1994), our
objective has been to obtain an accurate description for the
solution structure, including state of the art dynamics, of
zymogen PC in its complete calcium-bound, fully hydrated
configuration. The coordinates for the model are available
from the authors on request.
COMPUTATIONAL PROCEDURE
Model construction
The x-ray crystal coordinates of human APC (Protein Data Bank (pdb)
entry, 1aut), along with the crystallographic water molecules, were used to
model the initial structure of the zymogen form of human PC. The Gla
domain and the following aromatic helical stack were absent in the x-ray
crystal coordinates, as was the activation peptide. A flow chart of the
model building procedure, described below in detail, is given in Fig. 2. The
structure of the Gla domain of PC and the following aromatic helical stack,
was constructed by replacing the necessary residues of the x-ray crystal
FIGURE 1 Primary amino acid sequence of human PC deduced from
Foster et al. (1985). The domains are labeled according the definitions used
in the text. The catalytic residues are also (hatched) circled. Bold-faced
letters indicate the residues whose positions were initially modeled. ,
-carboxyglutamic acid residues; , -hydroxyaspartic acid.
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structure of factor VIIa (pdb entry 1dat) using SYBYL 6.4 (Tripos, Inc., St.
Louis, MO). The x-ray crystal structure of factor VIIa was determined in
the presence of tissue factor (TF) and the Gla domain does, in fact, interact
directly with TF, potentially causing a reorientation in the Gla-EGF1
orientation. Thus, the Gla-EGF1 orientation found in the factor VIIa/TF
complex may be unique for that particular system and may not necessarily
reflect the orientation of a general Gla-EGF interaction. The crystal struc-
ture is available for another VKD protein, porcine factor IXa, but the
electron density beyond the helical stack toward the N-terminus of the Gla
domain was not sufficient to resolve the Gla domain structure (Brandstetter
et al., 1995). In our current model, we construct the Gla segment based on
the x-ray crystal structure of the factor VIIa Gla domain, but link it to the
x-ray crystal structure of Gla-domainless PC so that the Gla-EGF1 orien-
tation is similar to that of the porcine factor IXa (pdb entry 1pfx). PC
residues Gln-49,Cys-50,Cys-69-Arg-91 and factor IXa residues Gln-50,
Cys-51, and Cys-62-Leu-84 (including -hydroxy aspartate (Hya)-71)
were used in the backbone atom alignment. Also, residues in the helical
stack at the C-terminal end of the Gla domain served to position the Gla
domain to the Gla domainless PC. Because the Gla domain of the x-ray
crystal structure of factor VIIa was mutated to create the Gla domain of PC,
the relative calcium positions were preserved. Using the calcium ion
coordinated to the EGF1 domain of factor VIIa as a template, a calcium ion
was introduced to the Gla-EGF1 connecting region of PC. An additional
calcium ion was introduced to the catalytic region (Mather et al., 1996) at
a site similar to the calcium binding site in trypsin.
During activation, a 12-residue polypeptide is cleaved from the zymo-
gen form of PC. In addition to the cleaved segment, modeling to determine
the coordinates for the final 9 residues from the C-terminus of the light
chain of APC (absent in the x-ray coordinate file due to disordered electron
density) was necessary. The complete activation loop was added in two
steps. First, it was necessary to redefine the N-terminus of the SP domain,
since this fragment is inserted into the body of the protein in the structure
of APC (x-ray). The N termini of available SP x-ray crystal structures in
their activated forms are remarkably similar. Fortunately, x-ray crystal
structures exist for the zymogen forms of several SPs; chymotrypsinogen
(Wang et al., 1985), prethrombin-2 (Vijayalakshmi et al., 1994), and
proproteinase E (Gomis-Ruth et al., 1995). In these zymogen structures, the
backbone atoms of key residues starting at residue 20 (chymotrypsin
numbering (cn)) are remarkably similar when superimposed. In Fig. 3, the
N-terminal segment of the SP domains of PC, chymotrypsin (pdb entry
4cha), -thrombin complexed with hirugen (pdb entry 1hah), porcine
pancreatic elastase (pdb entry 1btu) are compared. Backbone atoms of the
residues 20–25 (cn numbering) are used for the alignment. Also shown are
the zymogens; chymotrypsinogen (pdb entry 2cga), prethrombin-2 com-
plexed with hirugen (pdb entry 1hag), and proproteinase E in a ternary
complex with procarboxypeptidase A and chymotrypsinogen (pdb entry
1pyt). The N-termini of the active forms of these SPs align well. The
residues at position 16 in chymotrypsinogen and prethrombin-2 are found
to have a similar orientation. In proproteinase E, however, residue 16 is
orientationally rotated120°. Finally the residue at position 16 in all of the
activated SP systems is found at a relative orientation of 120° to both
chymotrypsinogen/prethrombin-2 and proproteinase. Thus, we were able to
reconstruct the N-terminus region of the catalytic domain of the zymogen
PC by overlaying it on the N-terminus of any of these three zymogen
systems. We chose to reconstruct the N-terminus region of PC by using the
corresponding residues of proproteinase E as a template. This choice
FIGURE 2 A flow chart summarizing the
model construction of zymogen PC from
the x-ray crystal structure (Mather et al.,
1996) of calcium-free Gla-domainless
APC.
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generally orients the initial model for the activation peptide toward the
putative calcium ion binding site in the catalytic domain (see later discus-
sion). The loop search algorithm in SYBYL6.4 Biopolymer package
(Tripos) was then used to introduce the AP between the C-terminus of the
light chain and the N-terminus of the catalytic domain. Twenty-five dif-
ferent loops were generated, of which 10 appeared reasonable. Of these, a
conformation that presented the pre-PC linking dipeptide (Lys-156-Arg-
157) as well as the scissile activation bond well exposed was chosen. This
conformation accommodates interaction of the AP with residues that
directly coordinate the SP domain bound calcium ion. All necessary
hydrogen atoms were added using the Protonate module of AMBER 5.0
(Case et al., 1997).
Simulation protocol
We initially energy minimized the structure around the PC/factor IX Gla
domain splice point (residues 34–46) and the structure surrounding the
calcium ion bound to the EGF1 domain, since part of the helical stack
(residues Ser-42, Asp-46, and Asp-48) contacts this calcium ion. Since the
remainder of the protein structure was based on the energy minimized
x-ray crystal structure, no additional segment-wise energy minimization
runs were necessary for backbone refinements. However, energy minimi-
zation of the side chains was employed (500 steepest descent steps fol-
lowed by 10,000 conjugate gradient steps). The protein (along with the
crystallographic water molecules and the calcium ions) was then solvated
in a box of water molecules so that the box boundaries were at least 12.5 Å
away from any protein atom. Water molecules used in the solvation of the
protein for which the oxygen or hydrogen atoms were within 2.0 Å of any
atom in the protein were excluded. The central simulation box contained
409 residues of the zymogen PC, 25,010 water molecules, and 9 calcium
ions. In addition to the calcium ions, six sodium ions were introduced as
free non-protein-bound counterions. These counterions did not coordinate
with any of the protein residues at any time during the MD simulation. The
simulation system was thus electrically neutral. The total number of atoms
in this box was 81,399. In the first step, only the added water molecules and
counterions were energy minimized at constant volume (10,000 conjugate
gradient steps), then all atoms except the protein were subjected to energy
minimization (another 10,000 conjugate gradient steps) and finally, the
whole system was energy minimized (10,000 conjugate gradient steps). All
atoms except those of the protein were subsequently subjected to a slow
heating procedure to bring the temperature of the system to 300 K. In this
heating procedure, the temperature of the system was raised by 50° at a
time in seven intervals of 1.5 ps each. After 25 ps of a constant volume-
constant temperature MD simulation, the system was reminimized (5000
conjugate gradient steps). After another heating run of 10 ps to bring the
temperature back to 300 K, a constant-temperature-constant volume MD
run was performed for 25 ps. Finally, a constant pressure-constant tem-
perature protocol was adopted to simulate 2900 ps of MD.
In the present study, we used the second generation of AMBER force
field (Cornell et al., 1995) in conjunction with the particle mesh Ewald
method (Essmann et al., 1995) to accommodate long range interactions in
all of the solution simulations. The TIP3P model was used to represent the
water molecules. The MD trajectory calculations were done with AMBER
version 5 (Case et al., 1997). Non-bonded cutoff for the direct sum was
chosen to be 8.0 Å. The time step was 1 fs with the nonbonded interactions
updated at every step. This choice of updating nonbonded interactions and
the periodical removal of the translational and rotational motions of the
center of mass (at every 2.5 ps) prevents artifacts such as the “flying ice
cube” (Harvey et al., 1998).
RESULTS AND DISCUSSION
Global aspects of the simulation
Our model for the zymogen form of human PC in solution
is based on the x-ray crystal structure of APC (Mather et al.,
FIGURE 3 The Ca alignment of
the N-terminal residues of activated
serine proteases: chymotrypsin,
-thrombin, bovine pancreatic elas-
tase, and PC. All the N-termini are
well superimposed for the above ac-
tive serine proteases; N labels the N-
terminal C of the active forms. The
C values of zymogens (preth-
ombin-2, chymotrypsinogen, and
proproteinase E) are also shown here.
Alignment uses residues 20–27(cn)
for all proteins. In chymotrypsinogen
and prethrombin-2, the residues cor-
responding to the AP of PC are found
to the left in the figure; the corre-
sponding residues of proproteinase E
exhibit a rotation of 120° to the right.
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1996). The Gla domain, the helical stack following the Gla
domain, the AP, and the calcium ions were aligned to the
x-ray crystal structure based on homology considerations.
The production runs were performed at constant pressure
and constant temperature. The density of the system was
found to fluctuate around 0.996 g/cc during the final 500 ps
of the 2.9-ns trajectory.
The root mean square deviations (RMSDs) of backbone
atoms from their initial positions (t  0 ps) have been used
to measure the stability of the simulation and to provide
insight into possible structure fluctuations (Hamaguchi et
al., 1992; Li et al., 1996; Perera et al., 1997). The RMSDs
for the complete protein and for certain selected substruc-
tural domains are presented in Fig. 4. The evaluation of
RMSDs of substructural domains is carried out after align-
ing appropriate residues from a conformation at time t, with
that at t  0 ps. For example, only Gla domain residues are
used for alignment in the calculation of RMSD for that
domain. The sharp rise observed during the first 800 ps in
the RMSD of all residues tends to flatten out but is subject
to transient fluctuations. The magnitude of this RMSD
curve, however, does not continue to increase for the final
2000-ps segment, implying that the protein structure is
stable over this time scale. Individual domains show rela-
tively smaller RMSDs and fluctuations. Small fluctuations
around the average values over the complete time period of
2900 ps is an indication of stable secondary structure.
We conclude that on the 3-ns time scale there are no
significant structural changes when going from crystal to
solution. The EGF1 domain displays slightly larger magni-
tude in RMSD. Similar large RMSD is found in the initial
1500 ps for the AP. The final 1-ns segment of the AP is
remarkably flat, implying that this region has reached its
equilibration during the first 1500 ps of dynamics. Although
the initial segment of the RMSD of the EGF1 domain rises
sharply during the first 200 ps, an eventual stabilization is
observed for this domain. Since part of the EGF1 domain
(second disulfide loop containing a Hya residue) was nec-
essarily modeled, it is not surprising that the early time
RMSD values were elevated. Likewise, the significant
changes to the coordinates of the N-terminus residues of the
EGF1 domain, modeled so as to align the Gla-EGF1 orien-
tation consistent with that of factor IXa, contribute to early
time RMSDs. Residues 137–169 (including AP residues
158–169) show somewhat larger fluctuations during the
first 1500-ps segment, but these become subdued during the
latter part of the trajectory. In general, domain-domain
movements are apparent in that the RMSDs increase as
domains are jointly considered (RMSD of light chain 
RMSD of {Gla  EGF1} or {EGF1  EGF2}  RMSD of
Gla or EGF1 or EGF2).
The relative dynamics of individual residues (-carbons)
that may not contribute to observable reorganization in
secondary structure can be investigated by computing the
atomic B-factors (York et al., 1994) using the variance,
r2, in the simulations through the relationship B 
[82/3]r2). The simulation B-factors were calculated us-
ing the coordinates of the last 200-ps segment of the MD
trajectory (Fig. 5). Since there is a tumbling of the molecule
within the central box, one must first remove this motion in
obtaining the average structure during the last 200 ps. The
simulation B-factors were computed by two different pro-
cedures; first by optimally aligning all backbone atoms with
those of the t  0 ps configuration (shown in solid lines)
and secondly by aligning backbone atoms of each domain
with the corresponding atoms of the t  0 ps configuration
(shown in dotted lines). It is clear that the latter procedure
is desired if domain-domain movement takes place. Rela-
tively smaller B-factors are apparent for the catalytic do-
main (residues 170–409), indicating a stable solution struc-
ture for this domain for the zymogen form (Fig. 5 b).
Although not exact, the experimental pattern for the peak
positions is largely conserved in the calculated B-factors
indicating the atoms with large motion in the x-ray crystal
structure remain mobile during the simulation. The patterns
in the calculated B-factors remain the same regardless of the
two methods used to calculate them, but the calculations
performed using the entire molecule for alignment show
FIGURE 4 The root mean square deviations (RMSDs) of the backbone
atoms. (a) All amino acid residues (dark solid line), the Gla residues 1–35
(filled circles), the EGF1 residues 48–92 (open triangles) and the EGF2
residues 93–136 (open squares). (b) The AP (residues including the con-
necting region; 137–169) (open triangles) and the SP domain (residues
170–409) (filled circles). (c) Combined Gla/EGF1 region (residues 1–91)
(open squares), combined EGF1/EGF2 region (residues 48–136) (filled
circles) and the entire light chain (residues 1–136) (dark solid line).
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slightly elevated B-factors. The segment 1–12 (	-loop res-
idues) at the N-terminus of the light chain shows relatively
large B-factors if the entire molecule is used in the align-
ment. There is a noticeable shift, however, in the baseline
from the N-terminal Gla region to the end of EGF1 domain.
This shift is not observed when the B-factors are calculated
using the alignment of individual domains. This baseline
shift originates from the interdomain motion among Gla,
EGF1, and EGF2 domains. Relatively larger peaks observed
in the dotted curve may be attributed to the intradomain
rearrangements. For example, the 	-loop as a region can
move without yielding a large perturbation to the Gla do-
main because of its protruding arrangement and, indeed, this
region shows larger B-factors. The same is true for the
central region of EGF1 domain where several residues are
involved in the binding of a calcium ion.
Light chain
The light chain of PC (Fig. 6 a) consists of three domains:
Gla (residues 1–37, Fig. 6 b), EGF1 (residues 49–91, Fig. 6
c), and EGF2 (residues 92–136, Fig. 6 d). A helical stack
(residues 37–48) connects the Gla domain to the first EGF
domain. The residues of this stack participate in the coor-
dination of the calcium ion bound to the first EGF1 domain.
Following the EGF2 domain, a 21-residue peptide (residues
137–157) connects the EGF2 domain to the activation pep-
tide (residues 158–169). This 21-residue peptide chain is
also linked to the SP domain through a disulfide bond.
The Gla domain and the helical stack (residues 1–47)
were missing from the N-terminal region in the x-ray crystal
structure of human APC (Mather et al., 1996). Since the
reported 3-D structure was of the activated form, the AP is
also absent (residues 158–169) and, due to diffuse electron
density, a peptide fragment from the C-terminal region of
the light chain was missing (residues 147–157). We recon-
structed the missing portions in our simulated protein using
homology modeling. The stability of the individual domains
can be examined by computing the differences between the
backbone  carbon positions in the initial and the final
configurations after 3-D alignments. In Fig. 7 a, the devia-
tions of C positions are measured by aligning a given
domain structure at the final configuration to the corre-
sponding domain structure at t 0 ps. On the average, most
residues remain near their initial C positions (deviations
around 1 Å). Smaller deviations occur for the residues in the
EGF2 domain. The segments that exhibit appreciable C
deviations include the N-terminal region of the EGF1 do-
main (residues 47–56). This region involved considerable
modeling to generate the structure, particularly for the cal-
cium ion in the EGF1 domain. The C deviations can also
be used as a measure for the domain separations. In Fig. 7
b, each domain of the final solution structure is aligned
separately to the corresponding domains of the solution
structure at t  0 ps. We display the curves after separate
helical stack, EGF1 and EGF2 alignments. Once the helical
stack (residues 34–48) is aligned (dark solid line), domain
motions in both sides are visible via their increased C
distances. Similar behavior is observed for EGF1 (dotted
line) and EGF2 (light solid line) alignments. We conclude
that the Gla, EGF1, and EGF2 domains have relative move-
ments during the trajectory, but each largely retains an
individual domain structure similar to the initial structure.
The Gla, EGF1, and EGF2 domains do not directly in-
teract via hydrogen bonds or salt bridges. Only the residues
in the connecting regions make direct hydrogen bonds with
the residues in the adjacent domains. Flexibility around the
connecting region results, though the integrity of the indi-
vidual domains are maintained. Even though there is inter-
domain motion, the length of the protein is relatively unal-
tered, because the motions are largely around the long axis
of the molecule.
In the initial modeling, the Gla-EGF1 orientation of por-
cine factor IXa was used to orient the Gla domain of PC
with its EGF1 domain. However, in the final structure of
PC, an orientation distinct from that of factor IXa is ob-
served. The light chain of PC, when compared with the
corresponding segments of factors VIIa (in the TF-bound
form) and IXa, has evolved to a shape between that of the
light chain of elongated factor VIIa and of curved factor IXa.
FIGURE 5 B-factors calculated for backbone C-atoms using the last
200-ps segment of the MD trajectory. (a) Light chain. (b) SP domain. The
B-factors were calculated by using the entire protein as a template for
alignment (dark solid lines) or after aligning individual domains and
combining data (dotted line). The domain definitions are given in the text.
X-ray B-factors are also shown (open circles). Interdomain motion, unless
removed, confounds B-factor evaluation.
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Gla domain
The Gla domain of human PC was modeled by making
necessary amino acid residue substitutions to the x-ray
crystal structure of factor VIIa (Banner et al., 1995, 1996)
calcium and TF bound, pdb entry 1dan. The calcium and
crystal water molecules were retained unmodified. In the
initial configuration, in which the Gla-EGF1 orientation is
similar to the x-ray crystal factor IXa-assumed alignment,
there are no direct hydrogen bonds, van der Waals contacts
or salt bridges among the residues of the two domains. As
has been indicated by the smaller magnitudes and fluctua-
tions in the RMSD as well as the small deviations of C
positions, the secondary structure of the Gla domain is not
altered from its original form (see Fig. 6 b, in which the Gla
domains of PC in the final structure and factor VIIa are
compared).
The 	-loop and the unique H-bond network at Ala-1,
which is tucked into the interior of the protein and makes
H-bonds with residues Gla-16, Gla-20, Ile-21 and Gla-26, is
maintained. Also, the Gla-calcium network that is found in
the structure of the Gla domains of VKD proteins (pro-
FIGURE 6 (a) The light chain
backbone structure created from the
last snapshot at t  2900 ps of the
trajectory. Calcium ions; light solid
spheres. The Gla and EGF1 domains
stack vertically; the EGF2 domain is
positioned perpendicular to the hypo-
thetical long axis of Gla and EGF1
domains. The SP domain (not shown)
positions on top of the EGF2 domain.
(b) The Gla domain backbone struc-
ture generated at t  0 ps (dark tube)
is superimposed with the final snap-
shot of the backbone atoms (light
tube) of the Gla domain. The calcium
ions correspond to the final structure.
(c) Same comparison as in b, but for
the EGF1 domain. (d) Same compar-
ison as b, but for the EGF2 domain.
All figures are generated using the
program Molscript (Kraulis, 1991).
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thrombin and factor VIIa) is well-preserved in the present
simulation. Of the seven calcium ions present in contact
with Gla residues, four have two or fewer coordinations
with water molecules. The remaining three Gla residues,
which are more solvent accessible, are coordinated with
three or more water molecules throughout the trajectory
calculation. The three hydrophobic residues (Phe-4, Leu-5,
and Leu-8) in the 	-loop extend away from the protein,
oriented for potential insertion into the lipid membrane.
Compared to the other VKD blood coagulation proteins,
human PC has a low PL (phosphatidylserine/phosphatidyl-
choline) binding affinity (Kd  1500 nM). Bovine PC and
human and bovine factor VIIa have been shown to have
even lower binding affinities toward lipid surfaces (Kd 
15,000 nM; McDonald et al., 1997a,b; Shen et al., 1997b).
It has been proposed (Shen et al., 1997b) that the lower
affinity of bovine PC is largely due to the presence of
proline at position 10 in place of His in human PC. How-
ever, in an experiment in which the first 46 residues in the
N-terminal region of PC is replaced by that of factor VII
(Geng and Castellino, 1997), the activated form of the
modified protein was found to be very similar to that of its
wild-type counterpart in plasma anticoagulant activity, as
well as activity toward inactivation of coagulation factor
VIIIa. All VKD coagulation proteins except factor VII and
PC contain a Gla residue in position 33. McDonald et al.
(1997) suggest that position 33 which is occupied by either
Gln (in PC) and Arg (in factor VII), may be responsible for
the low binding affinities. Also, the mutation of Ser-11, a
residue unique to human PC (in all other VKD coagulation
proteins it is Gly), to Gly yields increased membrane affin-
ity (Shen et al., 1998). The residues discussed above are
highlighted in Fig. 8. Assuming that the lipid binding of the
Gla domain is through a combined mechanism of PL inser-
tion of Phe-4, Leu-5, and Leu-8 (Christiansen et al., 1994,
1995a; Christiansen and Castellino, 1994; Jalbert et al.,
1996) and calcium bridging, one can assign the calcium ion
plane to be coplanar with the lipid head groups. Given this
conformation, His-10 could have an increased interaction
strength with the anionic lipid head groups since it can be
positively charged. Conversely, Ser-11 is placed so that it
blocks any incoming lipid headgroup from bridging with a
nearby calcium ion. Such a situation would reduce calcium
ion exposure with the charged lipid head groups, thereby
possibly reducing the lipid binding affinity of human PC.
Gla-26-Lys is a functionally defective mutation in human
PC found in the plasma of patients with hereditary throm-
bophilia (Nishioka et al., 1996). This mutant exhibits low-
ered activation rates and anticoagulant activity. Even
though defective APC and normal APC both displayed
similar PS binding, defective PC and its activated form do
not bind to phospholipids or cultured human endothelial
cells. The finding of Nishioka et al. (1996) suggests that a
Gla-26-dependent conformation is required for the binding
of PC or APC to PL membrane, the IIa/TM complex and the
FIGURE 7 (a) Deviations of -carbons of the corresponding light chain
residues in the active and zymogen (solution model) structures after opti-
mal alignments. Each domain is separately aligned. (b) C deviations for
the corresponding residues in the active and zymogen forms after aligning
only one domain at a time. Domain alignments are shown by dark solid
line, the helical hydrophobic stack (residues 35–48); dotted line, the EGF1
domain (residues 48–91); and light solid line, the EGF2 domain (residues
92–136).
FIGURE 8 A snapshot of the Gla domain (zymogen) viewed perpendic-
ular to the helical hydrophobic stack (residues 35–48) at t  2900 ps.
Important residues described in the text are marked using the stick repre-
sentation of bonds. The solid spheres represent the calcium ions. ,
-carboxyglutamic acid.
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surface of endothelial cell PC/APC receptor, but not for PS
interactions. In the zymogen PC conformation, we find that
Gla-26 is substantially involved in the Gla-calcium network
apparently required for membrane binding (Colpitts et al.,
1995). It is directed toward the interior of the protein where
several of the buried calcium ions are located, forming four
ionic bonds with three different calcium ions. Gla-26, along
with Gla-7, Gla-16, and Gla-29, coordinates three calcium
ions, whereas the other Gla residues have only one or two
calcium ions in their coordination shells. Particularly, Gla-
26, in concert with Gla-7 and Gla-16, may play an indirect
role on the formation of the 	-loop, since all bind to a
calcium ion that is in the immediate solvation shell of Ala-1.
Since the initial calcium ion positions were obtained from
the x-ray crystal structure of FVII/TF complex, and the Gla
residues are well preserved between FVII and PC, and also
based on our previous computational work on factor IX
calcium positioning that was used to guide the NMR exper-
imental data (Li et al., 1997), we are confident that the
calcium positions in our model after 3 ns may be near to
what one might find in the actual system.
The location of the active site of membrane-bound APC
relative to a PL surface has been determined using fluores-
cence resonance energy transfer (Yegneswaran et al., 1997).
In the absence of PS, the distance is found to be 94 
 3 Å.
The incorporation of PS, however, reduced this distance to
84 Å. Subsequent addition of PS did not change the distance
of the active site from the lipid surface for factors Xa, IXa,
and VIIa. The reduction in distance was attributed to the
cofactor function that apparently relocates the active site of
APC. In the present simulation, the active site of the zymo-
gen form of PC is about 89 Å above the hypothetical
membrane surface. To provide this conservative estimate,
we assume that the calcium ion plane resides on the mem-
brane surface for bridging interactions and the three hydro-
phobic residues (Phe-4, Leu-5, and Leu-8) are inserted into
the lipid membrane.
EGF1 domain
The main function of the EGF domains is likely to provide
protein-protein or protein-cell interactions (Hogg et al.,
1992). Cheng et al. (1997) evaluated the importance of the
functional interactions of the EGF1 residues of PC with
activators and substrates. They noted through mutational
studies that the charged residues of the EGF1 domain and
the calcium ion binding site maintain the structural integrity
of this module but these residues have little direct functional
interaction with activators or substrates. Also, the calcium
ion binding to the Gla domain does not seem to be influ-
enced by calcium ion binding to the EGF1 domain (Geng et
al., 1996; Cheng et al., 1997).
The EGF1 domain of PC differs somewhat from the
corresponding domain of other VKD coagulation proteins,
with the presence of an additional small loop (residues
59–63) created by a disulfide bond. This domain shows the
largest RMSD among the individual domains present in the
light chain (Fig. 4), but the alignment of the x-ray crystal
and solution backbone structures (Fig. 6 c) does not reveal
any global restructuring in this domain. The C deviations
(Fig. 7) for the EGF1 domain indicate that a significant
contribution to the RMSD for this domain may arise from
residues 52–57. Also, above average C deviations are
found in the region bracketing Hya-71. The calcium ion
present near the EGF1 domain (recall that we have modeled
and equilibrated this structural element) is doubly coordi-
nated with Hya-71 through two side chain carboxylate oxy-
gens. The only other residue from the EGF1 domain to
coordinate this calcium ion is Ile-73, via the backbone
carbonyl oxygen. Ser-42, Asp-46, and Asp-48 from the
connecting region between Gla and EGF1 domains also
coordinate with this calcium. One stable water molecule is
found in its coordination shell (Fig. 9 a). This calcium ion
maintains a stable eight-member coordination shell. As was
seen in the model of factor VIIa (Perera et al., 1999), the
geometry of the expanded coordination shell is a pentagonal
bipyramid in which carbonyl O of Ser-42, OD2 of Asp-46,
both OD1 and OD2 of Hya-71, and carbonyl O of Ile-73
define the pentagon; a water O is located at the bottom
vertex. OD1 and OD2 of Asp-48 share the other vertex. The
equatorial oxygen distances are found within 2.1 to 3.1 Å of
the neighboring ligands and the top and bottom vertex
oxygens maintain their distances to other complexing oxy-
gens between 3.0 and 3.8 Å. The water oxygen distances are
biased toward larger values, indicating that the calcium ion
maintains a one-sided, glove-like network with the protein
atoms. The EGF1 calcium ion appears to provide a pivot
point for Gla-EGF1 relative motion. In contrast, the SP
domain bound calcium ion (Fig. 9 b) is tightly surrounded
by 7 ligand oxygens in a square-bipyramidal environment
throughout the simulation.
Christiansen et al. (1995) showed that the helix-breaking
mutation of Ser-42-Pro results in a 35% reduction in
anticoagulant activity of APC (Christiansen et al., 1995b).
In an assessment of the role of the helical stack (residues
34–43), substitution of the helical stack of PC by that of
factor IX did not result in substantial changes in the Gla
domain-related calcium-dependent properties, suggesting
that the helical structural element plays a more important
role than the specific amino acids. The backbone of the
peptide fragment containing Hya-71 remains perpendicular
to the helical stack axis of hydrophobic residues (see Fig. 6
a). If we assume our present model, and if the hydrophobic
residues Phe-4, Leu-5, and Leu-8 do insert themselves into
the PL surface, then the Gla and EGF1 domains can be
viewed as a cylindrical column built on the inserted resi-
dues. We have observed a relative motion between the Gla
and EGF1 domains throughout the simulation. Interestingly,
we found smaller relative Gla-EGF1 motion in our simula-
tion study for the light chain of factor VIIa (Perera et al.,
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1999) in the absence of TF. The EGF1-bound calcium ion
and its coordinating residues are not in direct contact (no
salt bridges or hydrogen bonds) with residues that bind to
the calcium ions of the Gla domain. Thus, the simulation
structure is consistent with the experimental work of Cheng
et al. (1997), who concluded that no significant influence on
calcium ion binding of the Gla domain is found due to the
EGF1 calcium binding. Finally, the bulk of the EGF1 do-
main residues made no hydrogen bonds or salt bridges with
the neighboring Gla and EGF2 domains. However, Arg-91
in the connecting region between the EGF1 and EGF2
domains maintains strong contacts with both Glu-85 (in
EGF1) and Asp-101 (in EGF2). The lack of a number of
significant contacts with neighboring domains, however,
suggests the possibility of relatively low energy torsional
motions near the domain connecting regions.
EGF2 domain
The EGF2 domain (Fig. 6 d) is a stable region that does not
appear to undergo significant restructuring during the acti-
vation process. In fact, except for a few residues in the
N-terminal connecting region, most EGF2 residues exhibit
C deviations smaller than 1.0 Å from the x-ray crystal
structure (Fig. 7). In addition to the hydrogen bonds found
in the activated form of the x-ray crystal structure (Asn-
102/Arg-286, His-107/Thr-371, Tyr-108/Leu-278, and Cys-
109/Arg-286) between the EGF2 and SP domains, a hydro-
gen bond evolves between the EGF2 and SP domains of the
predicted solution structure of the zymogen form (Asp-101/
His-369). Despite the nearness of EGF2 to the catalytic
domain, direct contacts are limited.
Activation peptide (AP)
The AP of PC is the shortest (only 12 residues from Asp-
158 to Arg-169) of the VKD proteins that release an AP. It
contains 6 acidic residues and only one basic (Lys) residue,
and is therefore highly negatively charged. On the other
hand, the segment connecting the AP to the EGF2 domain
(residues 137–157) contains 8 Lys and Arg residues and
only one acidic Glu residue (charge  7e). This situation
creates a remarkable dipolar environment for this segment
of this protein. In fact, bovine PC carries only four Asp
residues whose charge is counterbalanced by two basic
residues present in the AP region, making this region still a
slightly acidic one. Still, the 23 amino acid residues that
connect the AP with the EGF2 domain of bovine PC contain
10 Lys and Arg residues to one Glu (charge  9e). APs
of both human and bovine forms of factors IX (35 AP
residues) and X (52 AP residues) are 3 to 4 times larger than
that of PC and contain an excess of 6 to 10 acidic residues.
For factors IX and X, the amino acid residues connecting
the AP to the EGF2 domain contain an excess of only 3 or
4 basic residues. Such differences among PC and other
VKD proteins in charge distributions around the scissile
bond may require different conditions for the initial ap-
proach of the zymogen to its enzyme for its activation. For
example, thrombin alone can activate PC but activation
rates are increased by at least 1000-fold in the presence of
TM. TM may thus enhance the electronegative environment
around the active site of thrombin. In this section, we
analyze the predicted structure of the AP (158–169) along
with the linker peptide (residues 137–157) that connects the
EGF2 domain to the AP. Despite the fact that this segment
is modeled, RMSDs were found to be comparable with the
other regions. Fig. 10 provides a snapshot (at t  2.9 ps) of
FIGURE 9 The final zymogen structure coordination spheres of the high
affinity calcium ions bound to (a) the EGF1 domain and (b) the SP domain.
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this region along with the backbone ribbon of the initial
configuration (t  0 ps).
PC is activated by IIa bound to TM on endothelial cells
(Esmon et al., 1993). Positively charged groups near the
catalytic site cleft of thrombin may directly interact with the
negatively charged AP in PC activation. Mutations of sev-
eral acidic residues in or near active cleft of thrombin
(Glu-217(cn)-Ala, Glu-192(cn)-Gln, and Glu-39(cn)-Lys)
result in increased IIa/PC interactions but have a little effect
on those with IIa/TM (Le Bonniec and Esmon, 1991; Le
Bonniec et al., 1991; Rezaie and Esmon, 1993). Mutations
of the acidic residues either to basic or neutral residues
increase the electropositivity of the electrostatic surface
around the thrombin catalytic cleft and favorably accom-
modate the negatively charged AP residues adjacent to the
scissile bond through enhanced electrostatic interactions.
Such movement would require the cleavage site of the AP
of zymogen PC to be exposed to the incoming thrombin (or
the IIa/TM complex). The AP cleavage site is readily avail-
able for such interactions in the present simulation structure
(solvent accessibilities are 114 and 107 Å2 for Arg-169 and
Leu-170, respectively). However, the P1 (Arg-169) residue
in the current final configuration has its side chain in a salt
bridge with Glu-232 in the calcium binding loop; this in-
teraction must complete with the P1-S1 interaction that
purportedly occurs at the active site of IIa.
In the present model, several H-bonds are found between
the AP and SP domains including several with the calcium
ion binding residues in the SP domain. Both Arg-229 and
Arg-230 of the SP domain interact with Asp-167 of the
activation peptide through H-bonds. Rezaie and Esmon
(1992) observed a twofold decrease in the maximum calci-
um-dependent fluorescence quenching due to the mutation
of Asp residues (to Gly) found at P3 (Asp-167) and P3
(Asp-172) positions (scissile bond  Arg-169—Leu-170).
Our simulation shows that Asp-167 can actively participate
in the stabilization of the SP calcium ion binding loop. Also,
in our current model Asp-172 interacts with Arg-314 via a
strong salt bridge. Similarly, Lys-233 interacts with both
Asp-161 and Glu-163. This network enhances the availabil-
ity of acidic residues in the calcium ion binding loop (res-
idues 225–235) for their calcium ion binding function by
moving side chains of the basic residues in this loop away
from the acidic residues. In addition, Trp-231 and Gln-165
also form a H-bond. Although the current simulation is of
benchmark size and duration, complete exploration of the
AP conformations may require a longer time scale than can
be simulated with current computer capabilities.
Serine protease (SP) domain
Because a major aim of the present simulation is to estimate
a reasonably accurate structure for the solution form of the
calcium-bound zymogen, comparison of the SP domain of
the modeled zymogen form with its crystallized activated
form may be useful in obtaining information about restruc-
turing that must occur near the catalytic residues on activa-
tion.
The SP domain of human PC consists of 240 residues.
The three most important residues (His-211, Asp-257, and
Ser-360, rendered in Fig. 11) define the functional role of a
SP. It is common, in SP domains of both coagulant and
anticoagulant SPs in the blood coagulation cascade, to ob-
serve the same global fold. The catalytic residues are lo-
cated at the junction between two interconnected six-
stranded -barrel domains. The SP domain of PC, along
with trypsin, coagulation factors II, VII, IX, and X, possess
a calcium ion binding site.
In modeling the SP domain for the zymogen form of PC,
two major modifications to the x-ray crystal configuration
of the activated form were introduced. Structural similari-
ties found among the crystal configurations of the SPs in the
blood coagulation cascade in their active and zymogen
forms were used in the creation of the N-terminal connec-
tion to the AP. All hemostatic proteases circulate in blood in
FIGURE 10 The activation peptide (resi-
dues 158–169) along with the connecting
region (residues 146–157) that follow the
EGF2 domain. The backbone (ribbon) at t
0 ps and the backbone atoms (sticks) at t 
2900 ps are displayed.
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the inactive zymogen form and become active due to spe-
cific cleavage after Arg-15(cn) in the SP. Several VKD
coagulation proteins (PC, factors IX and X) contain two
cleavage sites, and the removal of a small peptide takes
place during the process of their activation. Once cleaved,
the newly created N-terminus of the SP domain becomes
embedded in the SP interior. This structural element appar-
ently facilitates the charge transfer from Asp-102(cn) via
His-57(cn) to Ser-195(cn) required for PC catalytic activity.
In the zymogen x-ray crystal structure of proproteinase E
(and for two other zymogens considered), the N-terminal
residues of the catalytic domain points away from the pro-
tein with activation leading to insertion of the N-terminus
near the active site. The structure of proproteinase E was
adopted for the modeling of the N-terminal connecting
region of PC (the structure of three residues, Leu-
170(cn16), Ile-171(cn17), and Asp-172(cn18), are adapted
by this implementation), thereby introducing a significant
change to the SP domain of the APC template. Secondly, a
calcium ion, which is critical for zymogen activity, was
introduced to the region described in the literature (Mather
et al., 1996). We shall analyze the structural consequences
of these modifications.
As has been seen from Fig. 4, the RMSDs (zymogen
versus APC) calculated for the SP domain are small and
comparable with those of Gla and EGF2 domains indicating
a relatively stable solution structure (see also Fig. 11).
Considering that PC is in the zymogen form with no inhib-
itor present in the simulation (as opposed to the x-ray crystal
structure of APC with inhibitor present), this result is rather
unexpected. The RMSDs suggest that rearrangement in the
N-terminal region of the SP domain of APC does not lead to
large changes in the overall solution structure. There are,
however, differences in the side chain orientations (PC
versus APC) and several loops undergo movement.
The side chain motion can be studied with the help of
B-factors calculated for side chain heavy atoms. In Fig. 12,
we plot the side chain B-factors of the SP domain residues
averaged over the final 200 ps of the trajectory. The con-
figurations at each picosecond were aligned with the t  0
ps structure, and B-factors were then calculated for all
heavy atoms. Side chain B-factors of each residue were
calculated by averaging over all side chain heavy atoms
present. The experimental B-factors (averaged over the side
chain heavy atoms of each residue) are also given in Fig. 12
for comparison. The backbone B-factors (Fig. 5) calculated
from simulation are smaller in magnitude than the corre-
sponding B-factors calculated in x-ray experiments while
the computed side chain B-factors from the simulation show
either comparable or larger magnitudes than the x-ray ex-
periment. It is reasonable that the solvent environment may
lead to larger thermal fluctuations that translate to larger
B-factors (than experiment) observed for side chains in the
simulation. The general pattern of fluctuations in the calcu-
lated B-factors of the zymogen, however, is similar to that
observed in the x-ray crystal structure for APC. The solvent
accessibilities (and their changes) are shown in Fig. 12 to
ascertain whether there is a correlation between the B-
factors and the solvent accessibilities. The changes in the
solvent accessibility (SAA  SAA in the solution struc-
ture (zymogen)  SAA in the x-ray crystal structure (acti-
vated)) can identify residues that are newly exposed to the
solvent or new interactions that may accompany activation.
The patch containing three Lys residues, Lys-191(cn37) to
Lys-193(cn39), has large B-factors and also large solvent
accessibilities. This segment is recognized to be crucial for
FIGURE 11 The catalytic domains of PC in the
zymogen model (dark line) and the active x-ray
crystal structure (light line). Catalytic residues in
the zymogen model structure are rendered. Also,
loops with observed movements (APC 3 PC) in
the backbone structure are labeled.
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activation by IIa/TM complex but not by IIa alone (Gerlitz
and Grinnell, 1996). Though all of these Lys residues are
highly solvent accessible, once activated, Lys-192(cn38)
loses part of its solvent exposure. In another positively
charged patch of residues, Lys-217(cn62) and Lys-
218(cn63) show large side chain B-factors along with high
solvent accessibilities in zymogen PC. Upon activation,
these two residues become even more solvent-exposed (for
Lys-217(cn62) from 172 to 206 Å2 and for Lys-218 from 94
to 158 Å2). In the zymogen model Lys-217(cn62) forms a
H-bond with neighboring residue Ser-216(cn61) and
Lys-218(cn63) makes H-bonds with Leu-219(cn64) and
Asp-239(cn84). In the x-ray crystal form (APC), both are
unbound.
Cation binding to the SP domain
Rezaie et al. (1992) reported that the binding of the calcium
ion at the high affinity binding site in the SP domain of PC
results in a conformational change that is required for acti-
vation by the IIa/TM complex (Rezaie and Esmon, 1992;
Rezaie et al., 1992). This calcium ion binding site was
predicted to be near the 10 residue loop from Glu-225(cn70)
to Glu-235(cn80) (Mather et al., 1996). This segment
closely follows the structure of the calcium ion binding loop
of trypsin (Bode and Schwager, 1975). In our initial mod-
eled structure, the calcium ion was introduced to a six-
center coordination environment by ligating it with OE1 of
Glu-225(cn70), OE1 of Glu-232(cn77), OE1 and OE2 of
Glu-235(cn80), carbonyl oxygens of Asp-227(cn72), and
Arg-230(cn75). A seventh ligation position was occupied
by a water molecule as the simulation progressed. The
coordination shell of the calcium ion bound to the SP
domain is more compact than that observed for the EGF1-
domain bound calcium ion (see Fig. 9b). Mutation of Glu-
235(cn80)-Lys results in a form that no longer requires
calcium for rapid activation by the IIa/TM complex (Rezaie
et al., 1994). Presumably the calcium ion binding site is
disrupted. This mutation may, however, favorably change
the electrostatic potential around this putative calcium site
for incoming IIa/TM complex, much as the calcium ion does
in the wild-type structure. It remains to be shown if occu-
pancy of a calcium ion in this site is required for physio-
logical functioning of APC (He and Rezaie, 1999).
PC activation is also upwardly regulated by sodium ion
binding (He and Rezaie, 1999). He and Rezaie (1999)
identified a loop in APC similar to the sodium ion binding
loop of thrombin, and concluded that this loop may be
allosterically linked with the divalent cation binding loop of
the protease. We find that the sodium ion binding region
predicted by He and Rezaie (1999), residues 385–
390(cn221–225), is strongly electronegative via electro-
static potential surface computations (not shown). This loop
(residues 385–390) is remote from the putative calcium
binding site and we find no residues simultaneously shared
by both putative ion binding sites. We find, however, that
the putative sodium ion binding site is near the scissile bond
of PC activation (within 10 Å). Thus, sodium ion binding to
this site could modulate the electrostatics around the scissile
bond, thereby enhancing the interaction of the active site
cleft of thrombin. Further computational studies are cur-
rently under way in our laboratory to elucidate the effect of
this sodium ion on the SP domain structure.
Comparison of PC/APC with other known
zymogen/active SP pairs
C deviations for the solution zymogen model and x-ray
crystal structure of APC for the SP domain are given in Fig.
13. The residues that had crystal contacts with neighboring
APC molecules in the crystal configuration are marked in
this figure along with the residues that had inhibitor con-
tacts. Since the crystal contacts and inhibitor contacts are
removed in our solution model structure of the zymogen, the
residues that participated in contacts relax to yield some-
what larger C deviations (x-ray crystal APC x-ray versus
FIGURE 12 (a) Side chain B-factors averaged over the heavy atoms of
side chains of each residue of the catalytic domain (solid line) are com-
pared with those from the x-ray crystal structure of APC (shaded histo-
grams). (b) Solvent-accessible areas and (c) changes in the solvent-acces-
sible areas in going from zymogen to APC {(SAA)  SAAzymogen 
SAAAPC}.
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solution PC). On the other hand, for more than half (133) of
the residues, including two of the catalytic triad residues,
His-211(cn57) and Asp-257(cn102), in the SP domain have
C deviations 1 Å and only 48 residues (20% of the total
in this domain) have values 2 Å. The broad peak that
brackets residues 301–313(cn142–158) is likely due to re-
moval of crystal contacts, as most of the residues become
exposed to the solvent upon solvation. Other residues with
large deviations participate in forming hydrogen bonds and
salt bridges with the residues in the AP or the reconstructed
N-terminal part of the catalytic domain, for example, hy-
drogen bonds and salt bridges between Asp-167-Asn-
313(cn150), Asp-172(cn18)-Arg-314(cn151), and Lys-
174(cn20)-His-303(cn144)). Residues 350–358(cn186–
183) and 383–389(cn219–224) contribute to peaks in the C
deviations. These segments are linked by a disulfide bridge,
are near the 301–315(cn142–152) loop, and bracket resi-
dues that have inhibitor contacts and crystal contacts in the
x-ray crystal structure. The segment 385–390(cn221–225)
is the putative sodium ion binding site and the absence of a
sodium ion in the current simulation may contribute to some
disorder. Almost all regions that show elevated C devia-
tions contain residues exposed to solvent. Thus, differential
solvation apparently provides the most significant contribu-
tion to the C deviations observed in the present simulation.
The C deviations between PC (modeled) and APC
(x-ray) are compared (Fig. 14) with three other zymogen/
activated SP protein pairs for which the structures exist: a)
chymotrypsin (pdb entry 2cga)/chymotrypsinogen (pdb en-
try 4cha), b) prethrombin-2(pdb entry 1hag)/-thrombin
(pdb entry 1hah) (both active and zymogen forms are com-
plexed with hirugen), c) bovine proproteinase E (pdb entry
1pyt)/porcine pancreatic elastase (pdb entry 1btu). The ac-
tive site residues are already in their activated conforma-
tions in all of the activated systems, as is the case of PC.
Once the SP domain residues of PC are aligned with the
homologous residues of chymotrypsin, additional residues
of PC that do not have corresponding residues in chymo-
trypsin are found. These inserted residues are marked in Fig.
13 (dark circles in five separate segments). In Fig. 14, only
the first residue in each group was used to facilitate the
comparison. Removal of the Ca deviations corresponding to
these inserted residues from the plot does not change the
general characteristics of the plot (compare Figs. 13 and
14). Thus, the inserted residues of PC do not appear to alter
the structure common to these SP domains. The overall
picture that emerges from these comparisons is that the
deviations in the Ca values (PC versus APC) are similar to
the three available SP pairs.
Once superimposed, the backbone positions of the cata-
lytic triad residues of PC in the simulation structure are
essentially indistinguishable from the x-ray crystal structure
(RMSD of 0.5 Å) of APC. Comparison of the x-ray crystal
structures of the other zymogen/active SP pairs shows the
same fixed structure for catalytic triad residues. Unaltered
catalytic triad backbone atom positions among the activated
and zymogen serine proteases imply that during activation,
the local environment around the preformed catalytic triad
in the zymogen form of PC undergoes electrostatic and
steric changes suitable for enzymatic function. Such local
changes could provide the specificity of the enzymatic
reaction to a particular serine protease.
In the systems for which x-ray crystal data are available,
the loop cn186–194 has been proposed (Blow and Steitz,
1970) to play a key role in regulating enzyme activity. In the
FIGURE 13 Deviations of the -carbon atoms of the corresponding SP
domain residues of PC in the zymogen form and the active form after the
best alignment. PC numbering is used. Residues with crystal contacts (open
squares) and inhibitor contacts (diamond) in the x-ray crystal configuration
of the active form are marked. Filled circles indicate the presence of
additional residues (in APC) if aligned with chymotrypsin.
FIGURE 14 Comparison of the C deviations of PC (active versus
zymogen; shaded histogram) and (a) chymotrypsin/chymotrypsinogen, (b)
-thrombin/prethrombin-2, and (c) elastase/proproteinase systems (dark
solid lines). The backbone atoms of residues 24–238(cn) are used to align
the zymogen with its active form.
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active state, the N-terminus of the SP domain turns inward
after cleavage and interacts via a salt bridge with Asp-
194(cn), a neighbor of the catalytic residue Ser-195(cn)
(Blow and Steitz, 1970). A similar situation is observed for
APC: Leu-170(cn16) contacts Asp-359(cn194), also
through a salt bridge(Mather et al., 1996). The carboxylate
group and the amido nitrogen of Asp-194 in chymotrypsin
(Wang et al., 1985) and other SPs have an observable
rotation (approximately 140°) around the C-C bond
of Asp-194(cn) between zymogen and active forms (see
Fig. 15, a-c).
We initiated the PC simulation at a conformation similar
to the activated protein. Under normal simulation condi-
tions, it is not unreasonable to expect that an extremely long
trajectory calculation would be necessary to complete all of
the conformational changes in PC that are similar in mag-
nitude to the three experimental systems (zymogen/acti-
vated pairs). Currently available computational resources
cannot handle such lengthy simulations. Ultimately, im-
provements in sampling techniques may speed this process.
We observe a small rotation for the carboxylate group and
the amido nitrogen of Asp-194 (about 27°) during the first
1500 ps of the simulation (Fig. 15 d). Increase in the solvent
accessibilities of the neighboring residues to Asp-194(cn)
occurs. The C deviations at t  1500 ps indicate that
structural changes are underway and in a direction leading
to steric hindrance of the substrate binding site. The rate of
the Asp-194(cn) conformational change may be down-reg-
ulated by the Asp-194(cn) (side chain)/Cys-356(cn191)
(backbone) H-bond in the activated form and/or by the
FIGURE 15 Rearrangements around the s1 specificity pockets after zymogen activation: zymogen (dark tracing) and active protease (light tracing). (a)
Chymotrypsin/chymotrypsinogen. (b) Thrombin/prethrombin-2. (c) Elastase/proproteinase E. (d) APC/PC at t  1500 ps. (e) APC/PC at t  2900 ps.
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water molecules H-bonded to the protein. The time scale of
these refolding events may require a much more lengthy
simulation before the penultimate conformational changes
are observed. We subsequently forced this reverse transition
(activated during the 1500- to 1600-ps segment of the
trajectory) through step-wise constrained dynamics. All
constraints were relaxed after 1600 ps. Such a forced change
might have led to large positional fluctuations. The system,
however, responded favorably to this implemented change,
and no aberrations were observed in the following dynam-
ics, e.g., no large fluctuations in RMSD or B-factors.
Changes in the relative energies of the system before and
after this transformation are indistinguishable from the
noise level. The final configuration is given in Fig. 15 e. It
corresponds well with the zymogen orientations of this
fragment in the three experimental zymogen structures.
Because of the observed differences in substrate speci-
ficity, it is reasonable to expect dissimilarities near the
specific binding pockets. For instance, Met-192 of chymo-
trypsin moves from a deeply buried position in the zymogen
to the surface in the active form. In contrast, the SAA of
Glu-357(cn192) decreases from 124 Å2 in zymogen PC to
88 Å2 in APC. All the neighboring residues in APC simi-
larly have decreased SAAs. The region of the substrate
binding site in chymotrypsin that accommodates aromatic
and bulky nonpolar groups is not fully formed in its zymo-
gen (see Fig. 15 a). Fig. 15 e displays that in the predicted
zymogen form of PC, the loop comprising residues 186–
194(cn) restricts the accessibility of the active site. This is
consistent with the chymotrypsin/chymotrypsinogen case.
The “oxyanion hole” at the catalytic serine side chain re-
quired to stabilize the proposed tetrahedral transition state in
chymotrypsin is incomplete in chymotrypsinogen (Stryer,
1988). The same is true for the other two pairs as well as for
our final solution model of PC. Analysis of the APC and
chymotrypsin x-ray crystal structures yields similar struc-
tural arrangements around the catalytic serine.
Activation
Electrostatic potential surfaces can be useful in alignment of
interacting regions for incoming molecules. Specifically,
large electropositive or electronegative regions can reason-
ably attract oppositely charged entities through long-range
electrostatic interactions. The analysis of the calculated
electrostatic potential surfaces of the enzyme and substrate
separately may guide the relative alignment of the substrate/
enzyme complex. We have evaluated the electrostatic po-
tential surface of the calcium-bound PC zymogen model
(our substrate) using the popular code Grasp (Nicholls et al.,
1991; results not shown). Electrostatic potential surfaces of
the IIa/TM complex (pdb entry 1dx5) and IIa alone, after
removing TM from the IIa/TM complex, were also calculated.
The picture that emerges for the formation of the catalytic
complex from consideration of the structures and their elec-
trostatic potential surfaces is as follows. The active site cleft
of IIa is relatively electronegative. The concentration of
acidic residues near the PC scissile bond naturally imposes
a barrier for interaction with the active site of IIa. Due to the
SP calcium ion, Glu residues in the loop become interior
residues, while basic residues in this loop become exposed
and partially neutralize the acidic residues around the scis-
sile bond. Likewise, the basic residues in the fragment
connecting the AP to the EGF2 domain similarly provide
additional charge balancing for suitable IIa interaction. We
find that, viewed externally via Grasp, the scissile bond
region is actually positive. In fact, the comparison of the
electrostatic potential surfaces of the IIa/TM complex with
bare IIa after TM is removed, shows significant enhance-
ment in the electronegativity around the IIa catalytic site due
to TM. Since the binding of TM does not induce marked
allosteric structural changes in the vicinity of IIa catalytic
site (Fuentes-Prior et al., 2000), the increase of the negative
electrostatic potential around the catalytic site of IIa could
provide proper positioning of PC for its activation by IIa/
TM. Thus, the electrostatic potential surfaces via Grasp are
useful in providing an overview of complementarity that
accompanies the PC/IIa/TM complex formation.
SUMMARY
An equilibrated solution structure for the completely calci-
um-coordinated inactive zymogen form of human coagula-
tion protein C is developed. The initial structure is based on
x-ray crystallographic structure of the Gla-domainless acti-
vated form. The Gla domain (residues 1–48) is modeled
from the x-ray crystal coordinates of the factor VIIa/TF
complex and oriented with the EGF1 domain to yield an
orientation consistent with the x-ray crystal structure of
porcine factor IXa. The missing C-terminal residues in the
light chain (residues 147–157) and the AP (residues 158–
169) are introduced using homology modeling. MD simu-
lations (Amber-particle-mesh-Ewald) are used to approxi-
mate the complete calcium-complexed solution structure.
The individual domain structures of PC in solution are
largely unaffected by solvation, whereas joint domains
show relative movement during the trajectory. However, the
estimated height of the active site of the zymogen form
above the membrane plane is within the experimental esti-
mates. The Gla domain structure is similar to that of the
factor VIIa; thus, it may be reasonable to conclude that the
two proteins should show similar lipid binding properties.
The EGF1 and catalytic domain bound calcium ions in the
predicted solution structure show expanded and tightly
bound coordination shells, respectively.
Except for the N-terminal region of the catalytic domain,
the backbone atoms of the other catalytic domain residues in
active and zymogen forms yield a close alignment (RMSD
of 1.4 Å). The catalytic triad residues show a close back-
bone alignment for zymogen and active forms. The loop
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comprising residues 347–359(cn186–194) moves (active3
zymogen) so as to reduce access to the active site. The
positioning of the AP and the presence of the catalytic
domain bound calcium ion facilitate the electrostatics of
IIa/TM interactions in PC activation.
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